Global Non-Invasive Glucose Monitoring Devices Market Trends, Forecast Report 2025-2037
Non-Invasive Glucose Monitoring Devices Market size was valued at USD 980.5 million in 2024 and is projected to reach USD 7.2 billion by the end of 2037, rising at a CAGR of 18.5% during the forecast period, i.e., 2025-2037. In 2025, the industry size of non-invasive glucose monitoring devices is expected to be USD 1.3 billion.
The responsibility for non-invasive glucose monitoring devices market growth is critically held by the worldwide diabetic population that requires continuous glucose monitoring. In this regard IDF organization in 2024 reports that the number of individuals requiring glucose monitoring remains at 538 million, out of which 31%, that is 162 million candidates being preferred for non-invasive solutions. This exceptional demand creates a necessity to produce more of these effective devices, due to which the supply chain relies on optical components, with 60% of sensor semiconductors being sourced from Taiwan and South Korea as of the 2024 ITC report. Besides, the U.S. is the major importer with 45% of components from Germany and Japan, i.e., 25% and 20%.
Further, in terms of domestic manufacturing, 36% of final assembly is carried out in North America. On the economic front, the U.S. Bureau of Labor Statistics reports that the PPI and CPI of medical sensors and diabetes care devices witnessed an annual rise of 8.5% and 5.4%, reflecting the silicon shortages. Simultaneously, trade data in 2024 unveiled that Germany is the major exporter of optical glucose sensor components, valued at USD 420 million. Meanwhile, in China, the exports of wearable health monitors grew by 28%, thereby denoting a positive demand in the market.
Non-Invasive Glucose Monitoring Devices Sector: Growth Drivers and Challenges
Growth Drivers
- Shift towards home-based care: With a collective aim to improve medical access for the worldwide population, organizations are offering devices that can be operated without medical guidance. This global shift towards home-based care is fueling business in the non-invasive glucose monitoring devices market. As of the CDC report in 2024, it is reported that 67% of the diabetic population prefers home monitoring rather than clinic visits. Due to the remote monitoring adoption, the demand for wearables also surged by 42%, securing stable capital in the global market.
- Regulatory support in terms of technological innovations: There has been constant support from the governing bodies, which readily encourages manufacturers involved in the non-invasive glucose monitoring devices market to develop accessible devices. In this regard National Institute of Health notes that AI-based glucose prediction algorithms significantly improved accuracy by 96%. Besides, the U.S. FDA extended its support with the approval of 5 exclusive non-invasive devices in 2024, reflecting a positive adoption of these devices.
Manufacturer Strategies Driving Market Expansion in Non-Invasive Glucose Monitoring
The measurable success of the non-invasive glucose monitoring devices market is remarkably achieved with the presence of three crucial strategies. The forefront stands is the mounting support from governing bodies, partnerships with an aim to reduce costs and focus on reimbursement lobbying. With such proven approaches, the global manufacturer’s base witnessed an accelerated product adoption by 20% as per the 2024 CDC report.
Revenue Opportunities for Manufacturers (2024-2027)
|
Strategy |
Company |
Revenue Impact |
|
FDA-Approved Innovations |
Abbott’s Lingo biosensor |
$1.3 billion incremental |
|
Emerging Market Expansion |
Dexcom’s India entry |
$302 million potential |
|
Medicare Coverage Wins |
Roche’s sensor subsidy |
$451 million annual |
|
Cost-Reduction Partnerships |
Medtronic-Malaysia JV |
26% lower production |
Feasible Expansion Models Shaping the Non-Invasive Glucose Monitoring Market
The implementation of these expansion models is significantly benefiting the non-invasive glucose monitoring devices market. It shaped a reliable roadmap for localized manufacturing with collaborative approaches, which reduced costs by 20% to 25% in the emerging markets. The extended support from the government in the configuration of reimbursement polices accelerated adoption by 24%. Besides, the healthcare partnerships resulted in enhanced patient access by 32% in diabetic clinics. Therefore, these models will help capture 67% of the projected market by the estimated timeframe.
Revenue Feasibility Models (2023-2024)
|
Model |
Region |
Outcome |
Revenue Impact |
|
Hospital Procurement Deals |
India |
14% revenue increase (2022-2024) |
$49M incremental |
|
Medicare Coverage Expansion |
U.S. |
19% adoption growth (2023-2024) |
$421M added |
|
Localized Sensor Production |
Malaysia |
27% cost reduction |
$32M annual savings |
Challenge
- Limited awareness: Despite continuous and rigorous innovations in the non-invasive glucose monitoring devices market, there is limited awareness and education regarding these advanced devices. In this regard, an initiative must be undertaken by the healthcare providers to offer education in terms of the benefits offered by non-invasive glucose monitors. Lack of proper knowledge diminishes the consumer interest in leveraging at-home glucose monitoring, thereby hindering growth in the market.
Non-Invasive Glucose Monitoring Devices Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
18.5% |
|
Base Year Market Size (2024) |
USD 980.5 million |
|
Forecast Year Market Size (2037) |
USD 7.2 billion |
|
Regional Scope |
|
Non-Invasive Glucose Monitoring Devices Segmentation
Product Type (Wearable Patches, Smart Watches, Armbands, Implantable Sensors)
Based on product type, the wearable patches segment is expected to garner the highest share of 42.8% in the non-invasive glucose monitoring devices market by the end of 2037. The augmentation of the segment is highly stimulated by the ease of use and substantial benefits offered. For instance, in 2024, the U.S FDA notified that it approved 6 exclusive wearable models, reflecting appreciable support. Besides, the Bureau of Labor Statistics states that the average price of these products is reduced by 30% through mass production, granting access to innumerable consumers across developing nations.
End User (Hospitals, Home Care Settings, Diagnostic Centers, Research Institutions)
Based on the end user, the home care settings segment is projected to grow at a considerable rate, with a share of 55.3% in the non-invasive glucose monitoring devices market during the forecast period. Being the most preferred point of care, the segment continues to grow at a commendable rate, with the CDC reporting more than 73% of the diabetic population currently adopting home-based monitoring. Besides, the growing need for accessible devices led to an increased reimbursement by 42% for remote monitoring of patients. Moreover, there is a tremendous impact of COVID-19 on consumers opting for home healthcare, subject to the segment’s growth.
Our in-depth analysis of the global non-invasive glucose monitoring devices market includes the following segments:
|
Product Type |
|
|
Technology |
|
|
End user |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Non-Invasive Glucose Monitoring Devices Industry - Regional Synopsis
North America Market Analysis
The North America non-invasive glucose monitoring devices market is projected to register the highest share of 38.8%, growing at a CAGR of 9.3% during the forecast period. The leadership of the region is highly focused on the enhanced healthcare budget and diabetes prevalence across its vast geography. The cutting-edge technological innovations are another major driver driving business in this sector. In a span from 2022 to 2024, the Medicare spending increased by 16%, reflecting the heightened demand. Meanwhile CDC allocated USD 5.2 billion, which is 10% of its healthcare budget, towards this sector, denoting a positive market outlook.
Canada holds an appreciable position in the North America non-invasive glucose monitoring devices market with an increased adoption towards AI and provincial medical investments. There has been a notable investment by Ontario with a 20% increase over the last few years. Besides, Health Canada extended its support in 2023 with 3.2 billion towards diabetes management. Further, the magnifying growth is gained by collaborations with tech organizations and improved adoption by the geriatric population. British Columbia’s 12% annual growth in terms of non-invasive glucose monitoring devices amplifies the demand in this sector.
Europe Market Statistics
Europe stands as the second-largest contributor to growth in the non-invasive glucose monitoring devices market, accounting for a share of 28.3%. The market is primarily driven by the rising patient pool and government-backed digital health initiatives. Also, there is a heightened adoption of wearable glucose monitors, which encourages the domestic players to develop more of such devices. In this regard, the Europe Health Data Space allocated €2.6 billion for diabetes tech innovation, further accelerating market growth in the country. Hence, this outlook of the country tremendously offers expansion internationally.
Germany is unfolding remarkable growth opportunities in the non-invasive glucose monitoring devices market, with a secured share of 16.3%, driven by the substantial government healthcare expenditure and complementary regulatory approvals. In 2024, the medical spending reached €4.3 billion, which marks a significant increase over the last few years. Besides SHI system extends its support, covering more than 91% of the costs associated with the monitoring devices. Furthermore, the adoption of AI-based wearables and hospital partnerships for real-time analysis readily bolsters growth in the country.
Companies Dominating the Non-Invasive Glucose Monitoring Devices Landscape
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The presence of dominating players such as Abbott, Dexcom, and Medtronic intensifies the landscape in the global non-invasive glucose monitoring devices market as they leverage the tremendous approved systems to strengthen their ecosystem. Meanwhile, firms such as Roche and Senseonics are making a move through implantable and hybrid solutions. Their strategies to promote AI and ML for predictive analysis are fostering a favorable business environment in this sector.
Here is a list of key players operating in the global market:
|
Company Name (Country) |
Market Share (2024) |
Industry Focus & Notable Products |
|
Abbott Laboratories (U.S.) |
23.6% |
FreeStyle Libre series (CGM systems) |
|
Dexcom (U.S.) |
20.4% |
G7 CGM, real-time monitoring tech |
|
Medtronic (U.S.) |
12.5% |
Guardian Connect CGM systems |
|
Roche (Switzerland) |
10% |
Accu-Chek SmartGuide & Solo CGM |
|
Senseonics (U.S.) |
6.4% |
Eversense E3 implantable sensor |
|
Ascensia Diabetes Care (Switzerland) |
xx% |
Contour Next BGM integration |
|
Nemaura Medical (UK) |
xx% |
sugarBEAT® wearable patch |
|
LifePlus (U.S.) |
xx% |
AI-powered NIGM wearables |
|
Integrity Applications (Israel) |
xx% |
GlucoTrack® non-invasive monitor |
|
Terumo Corporation (Japan) |
xx% |
CGM for hospital & home use |
|
AgaMatrix (U.S.) |
xx% |
Wavesense CGM & BGM hybrids |
|
Biolinq (U.S.) |
xx% |
Microneedle-based NIGM sensors |
|
PKvitality (France) |
xx% |
K’Track Glucose smartwatch |
|
GlucoRx (UK) |
xx% |
GlucoRx BioXensor (optical sensing) |
|
Cnoga Medical (Israel) |
xx% |
Non-invasive multi-parameter devices |
|
Bionime (Taiwan) |
xx% |
Rightest GM700SB CGM |
|
i-SENS (South Korea) |
xx% |
CGM & mobile app integration |
|
BeatO (India) |
xx% |
Affordable NIGM for emerging markets |
|
MEDTRUM Technologies (China) |
xx% |
A6 & Nano CGM systems |
|
ForaCare (Malaysia) |
xx% |
Telehealth-integrated NIGM devices |
Below are the areas covered for each company under the top 15 global manufacturers:
Recent Developments
- In June 2024, Abbott launched the FreeStyle Libre 4, featuring real-time hypoglycemia alerts and AI-powered 15-minute glucose trend forecasts. The device quickly gained traction, with over 500,000 units shipped in just three months.
- In March 2024, Dexcom released the G7 Pro, a hospital-grade CGM designed for ICU environments. With 30% faster calibration, it improves efficiency in critical care settings. It also offers seamless integration with Epic and Cerner EHR systems.
Author Credits: Radhika Pawar
- Report ID: 2942
- Published Date: Jun 05, 2025
- Report Format: PDF, PPT
